Rexulti

Rexulti

brexpiprazole

Manufacturer:

Lundbeck

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Brexpiprazole
Indications/Uses
Schizophrenia in adult patients. Adjunctive therapy to antidepressants for major depressive disorder (MDD) in adult patients.
Dosage/Direction for Use
Schizophrenia Recommended target dose range: 2-4 mg once daily. Initially 1 mg once daily on days 1-4. Titrate to 2 mg once daily on days 5-7, then to 4 mg once daily on day 8. Max: 4 mg daily. Maintenance dose range: 2-4 mg daily. Adjunctive treatment of MDD Initially 0.5 or 1 mg once daily. Titrate to 1 mg daily & up to target dose of 2 mg daily at intervals of up to 1 wk. Moderate to severe hepatic impairment (Child-Pugh score ≥7) & moderate, severe or end-stage renal impairment (CrCl <60 mL/min) Schizophrenia Max: 3 mg once daily. MDD Max: 2 mg once daily.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Hypersensitivity. Not indicated for dementia-related psychosis. Discontinue use if neuroleptic malignant syndrome occurs & absolute neutrophil count <1,000/mm3. Suicidal risk, thoughts & behaviours; tardive dyskinesia; metabolic changes including hyperglycemia, DM, dyslipidemia & wt gain; elevated prolactin levels; rare cases of priapism; venous thromboembolism; leukopenia, neutropenia & agranulocytosis; orthostatic hypotension & syncope; QT prolongation; falls; seizures; body temp regulation; pathological gambling & other compulsive behaviours. Patients w/ known CV & cerebrovascular disease, conditions predisposing patients to hypotension or HTN; at risk of aspiration pneumonia; history of or at risk of sleep apnea. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. May affect ability to drive & use machines. Hepatic & renal impairment. Pregnancy & lactation. Ped patients. Elderly patients w/ dementia-related psychosis.
Adverse Reactions
Increased wt; akathisia, tremor, dizziness. Schizophrenia: Diarrhoea, nausea; increased blood creatinine phosphokinase; back pain. MDD: Blurred vision; constipation, dry mouth; fatigue; nasopharyngitis; increased appetite; somnolence; restlessness, insomnia, anxiety.
Drug Interactions
Increased exposure w/ strong CYP3A4 inhibitors (eg, itraconazole, clarithromycin, ketoconazole) & CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine). Decreased exposure w/ strong CYP3A4 inducers eg, rifampin, St. John's wort.
MIMS Class
ATC Classification
N05AX16 - brexpiprazole ; Belongs to the class of other antipsychotics.
Presentation/Packing
Form
Rexulti FC tab 4 mg
Packing/Price
28's
Form
Rexulti FC tab 3 mg
Packing/Price
28's
Form
Rexulti FC tab 2 mg
Packing/Price
28's
Form
Rexulti FC tab 1 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in